Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

Semaglutide

metabolicweight-lossfat-loss
Regulatory status — FDA-approved for indicated use

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist available in subcutaneous injectable and oral formulations, approved for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Clinical trial evidence demonstrates meaningful reductions in major adverse cardiovascular events, kidney disease progression, HbA1c, and body weight, with an established gastrointestinal adverse event profile. Emerging safety signals — including a potential association with non-arteritic anterior ischaemic optic neuropathy and rare respiratory complications — warrant clinical vigilance.

Evidence coverage

44/67 claims verified by independent fact-checker.

10 claims pending coverage
  • Evidence tier below threshold(6 claims)
  • FDA prescribing-label data(3 claims)
  • Source 929803ec (NLRP3 inhibition by VTX3232 in obese mice) studies a pharmacological NLRP3 inhibitor (VTX3232), not semaglutide. Attributing semaglutide's mechanism to NLRP3 inhibition based on this source is a claim-source mismatch. The source does not support the specific claim as written.(1 claim)

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
1 week
Typical dose
0.5-1mg/wk SC
Route
multiple
Frequency
Once weekly (subcutaneous formulations used in cardiovascular and glycemic outcome trials) [1] [11]; once daily (oral formulation) [8].
Cycle length
—
Evidence strength
Phase III RCTs

Suggested labs for this peptide class — educational reference only; not medical advice.

Official prescribing information

The following sections are reproduced from the FDA-approved prescribing information. This is the authoritative clinical record — not editorial content.

Approved use(s)

OZEMPIC is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus…

Dosing & administration

Inspect OZEMPIC visually before use. It should appear clear and colorless. Do not use OZEMPIC if particulate matter and coloration is seen. Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals. Inject OZEMPIC subcutaneously in the abdomen, thigh, o…

Warnings & precautions

In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including M…

Contraindications

OZEMPIC is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2. [see Warnings and Precautions ( 5.8 )] A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and a…

Drug interactions

OZEMPIC stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving OZEMPIC in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. 6 When initiating OZEMPIC, co…

Adverse reactions

The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors 5.2) [see Warnings and Precautions (] Acute Pancreatitis Diabetic Retinopathy Complications Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Acu…

Source: FDA-approved prescribing information for Ozempic, last updated October 14, 2025. View original at DailyMed →

TL;DR

  • Half-life: 1 week — dosed —.
  • Administered via multiple.
  • Evidence base: randomised controlled trials.
  • Primary goals: metabolic, weight-loss, fat-loss.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Randomised controlled trials

How we evaluate evidence →

How it works

GHRH analogues stimulate pulsatile GH release from the pituitary, elevating IGF-1 and promoting fat oxidation.

Semaglutide is a long-acting analogue of the endogenous incretin hormone GLP-1, engineered with a fatty acid side chain that enables albumin binding and prolongs half-life [16]. By binding GLP-1 receptors on pancreatic beta cells, it augments glucose-dependent insulin secretion and suppresses glucagon release, lowering postprandial and fasting glycemia [16]. Animal studies indicate semaglutide also improves insulin sensitivity and beta-cell identity independent of body weight effects [17]. Mechanistic data from mouse models points to differential cardiometabolic and hepatic effects mediated through endothelial and hematopoietic cell GLP-1 receptor expression [18]. In vitro evidence indicates semaglutide improves mitochondrial function and insulin sensitivity in muscle cells at pharmacokinetically attainable concentrations [19]. Animal studies suggest semaglutide reduces body weight, hyperglycemia, and hepatic steatosis partly through NLRP3 inflammasome inhibition [20]. Mechanistic data from T2DM models point to remodeling of adipose tissue through improved lipid handling, reduced inflammation, and enhanced mitochondrial function [21]. A systematic review of preclinical and mechanistic evidence suggests GLP-1 receptor agonists including semaglutide may target tau hyperphosphorylation and beta-amyloid accumulation relevant to Alzheimer's pathophysiology, though human randomized trial data in this indication are absent [13].

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Medical history
  • No personal or family history of medullary thyroid carcinoma or MEN2 [16]
  • No history of acute pancreatitis or recurrent pancreatitis episodes [7]
  • No unexplained or severe respiratory compromise [12]
  • Ophthalmologic status documented if history of diabetic retinopathy or optic neuropathy [6]
Laboratory baseline
  • HbA1c measured [15]
  • Renal function (eGFR, urine albumin-to-creatinine ratio) assessed [1]
  • Liver enzymes (ALT, AST) documented where metabolic liver disease is suspected [9]
  • Fasting lipid panel obtained for cardiovascular risk stratification [1]
Lifestyle readiness
  • Resistance exercise program planned or initiated to help preserve lean mass [5]
  • Adequate dietary protein intake discussed with clinician or dietitian [5]
  • Patient counseled on expected gastrointestinal adverse events during dose escalation [4]
Prescriber and monitoring plan
  • Prescribing clinician identified with appropriate prescribing authority
  • Follow-up schedule established for HbA1c, weight, and adverse event monitoring [15]
  • Patient informed of GI adverse event profile and discontinuation rates observed in real-world settings [4]
  • Patient informed of observational NAION signal and instructed to report new visual symptoms [6]
  • Assess baseline HbA1c, renal function, liver enzymes, and cardiovascular risk profile prior to initiation [15]
  • Screen for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as these represent contraindications for GLP-1 receptor agonist class [16]
  • Evaluate for history of acute pancreatitis, as case reports document semaglutide-associated acute pancreatitis [7]
  • Obtain ophthalmologic assessment if history of diabetic retinopathy or optic neuropathy is present, given mixed observational safety signal [6]
  • Discuss lean mass preservation strategies including resistance exercise and adequate protein intake before starting therapy, as an RCT protocol (LEAN-PREP) is actively studying this [5]

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • Monitor for gastrointestinal adverse events, particularly during dose escalation; real-world cohort data confirm dose-related discontinuation rates [4]
  • Monitor HbA1c and fasting glucose at regular intervals; a Phase 3 RCT demonstrated non-inferiority of generic semaglutide on HbA1c reduction at 24 weeks [15]
  • Monitor liver enzymes where hepatic steatosis or metabolic liver disease is a concern; preliminary open-label data report hepatic biomarker improvements over 24 weeks [9]
  • Monitor for unexplained respiratory symptoms; a case report documented hypercapnia with respiratory acidosis in a semaglutide user [12]
  • Monitor for visual changes; report new visual disturbances promptly given the observational NAION signal [6]
  • Engage in resistance exercise and maintain adequate protein intake during therapy to mitigate lean mass loss, as formally studied in the LEAN-PREP trial protocol [5]

After — Post-cycle

  • Long-term efficacy and safety data beyond 2 years of continuous semaglutide use are limited; the durability of cardiometabolic benefits after discontinuation has not been established in the available research packet
  • Weight regain after discontinuation is a recognized class concern; an ongoing research focus examines body weight trajectory after stopping GLP-1 receptor agonist therapy [14]
  • Continue monitoring cardiovascular and renal parameters after cessation, particularly in high-risk patients [1]

Stacks it appears in

Semaglutide + Intranasal insulin (investigational combination for cognition in older adults with metabolic syndrome — feasibility trial only, not clinically established) [src:e1d45418-111f-4103-819e-872244eeeddd]
SemaglutideIntranasal insulin (investigational combination for cognition in older adults with metabolic syndrome — feasibility trial only, not clinically established) [src:e1d45418-111f-4103-819e-872244eeeddd]
metabolic
Semaglutide + Colchicine (studied alongside semaglutide for atrial remodeling in rat heart failure models — animal data only) [src:c51a40bb-351c-4179-a92a-18e69cb2d436]
SemaglutideColchicine (studied alongside semaglutide for atrial remodeling in rat heart failure models — animal data only) [src:c51a40bb-351c-4179-a92a-18e69cb2d436]
metabolic
Semaglutide + Resistance exercise and high-protein diet (protocol under RCT investigation for lean mass preservation during semaglutide therapy) [src:0c779ad2-eb5d-46b6-bf66-e61bb7e8a75c]
SemaglutideResistance exercise and high-protein diet (protocol under RCT investigation for lean mass preservation during semaglutide therapy) [src:0c779ad2-eb5d-46b6-bf66-e61bb7e8a75c]
metabolic

Related peptides

Other compounds indexed on Pepteligence that share research tags with Semaglutide. Educational context only.

Tirzepatide

Tier 1
metabolicweight-lossfat-loss

Tesamorelin

Tier 1
metabolicfat-loss

Liraglutide

Tier 1
metabolicweight-loss

MOTS-c

Tier 3
metabolic

Safety

Common side effects

  • ·Nausea — reported as a leading cause of dose-related discontinuation in real-world cohort data [4]
  • ·Vomiting — documented with dose escalation in real-world and trial settings [4]
  • ·Diarrhea — reported in real-world cohort and trial populations [4]
  • ·Lean mass reduction — significant loss of lean body mass observed alongside fat mass loss during semaglutide therapy [5]

Rare side effects

  • ·Acute pancreatitis — case reports document semaglutide-associated acute pancreatitis in patients with T2DM and additional risk factors [7]
  • ·Hypercapnia with respiratory acidosis — documented in at least one case report of a patient without diabetes receiving semaglutide 1 mg weekly; mechanism remains unclear [12]
Safety notice — Serious / theoretical risks:
  • Non-arteritic anterior ischaemic optic neuropathy (NAION) — an observational safety signal links GLP-1 receptor agonists including semaglutide to NAION; a critical review of the evidence notes it remains mixed and confounded, and a definitive causal link has not been established [6]
  • Acute pancreatitis (serious manifestation) — while documented as rare, pancreatitis carries potential for life-threatening complications and warrants prompt evaluation if abdominal pain develops [7]

Contraindications

  • ·Personal or family history of medullary thyroid carcinoma — GLP-1 receptor agonist class contraindication [16]
  • ·Multiple endocrine neoplasia syndrome type 2 (MEN2) — GLP-1 receptor agonist class contraindication [16]
  • ·History of acute pancreatitis or pancreatitis-related episodes — case reports document semaglutide-associated acute pancreatitis [7]
  • ·Unexplained severe respiratory symptoms or documented respiratory compromise — a case of hypercapnia with respiratory acidosis has been reported [12]
  • ·History of non-arteritic anterior ischaemic optic neuropathy (NAION) or recent optic/eye surgery — based on a mixed but present observational safety signal; evidence is not conclusive [6]

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for Semaglutide. Be the first to share yours.

Share your experience →

Have you tried Semaglutide?

Share your protocol and outcome to help build the community dataset.

Share your experience →

Semaglutide — at a glance

PropertySemaglutide—
Half-life1 week—
Routemultiple—
Typical dose0.5-1mg/wk SC—
MechanismSemaglutide is a long-acting analogue of the endogenous incretin hormone GLP-1, engineered with a fatty acid side chain that enables albumin binding and prolongs half-life. By binding GLP-1 receptors on pancreatic beta cells, it augments glucose-dependent insulin secretion and suppresses glucagon release, lowering postprandial and fasting glycemia. Animal studies indicate semaglutide also improves insulin sensitivity and beta-cell identity independent of body weight effects. Mechanistic data from mouse models points to differential cardiometabolic and hepatic effects mediated through endothelial and hematopoietic cell GLP-1 receptor expression. In vitro evidence indicates semaglutide improves mitochondrial function and insulin sensitivity in muscle cells at pharmacokinetically attainable concentrations. Animal studies suggest semaglutide reduces body weight, hyperglycemia, and hepatic steatosis partly through NLRP3 inflammasome inhibition. Mechanistic data from T2DM models point to remodeling of adipose tissue through improved lipid handling, reduced inflammation, and enhanced mitochondrial function. A systematic review of preclinical and mechanistic evidence suggests GLP-1 receptor agonists including semaglutide may target tau hyperphosphorylation and beta-amyloid accumulation relevant to Alzheimer's pathophysiology, though human randomized trial data in this indication are absent.—
Evidence strengthrctanecdotal
Primary goalmetabolic—

Frequently asked questions

What is semaglutide?
Semaglutide is a long-acting analogue of the endogenous incretin hormone GLP-1. It is FDA-approved for treatment of type 2 diabetes mellitus and obesity, and is available in subcutaneous injectable and oral tablet formulations under three brand names.
How does semaglutide work?
Semaglutide is engineered with a fatty acid side chain that enables albumin binding and prolongs its half-life. By binding GLP-1 receptors on pancreatic beta cells, it augments glucose-dependent insulin secretion and suppresses glucagon, lowering both postprandial and fasting glycemia.
What is semaglutide FDA-approved for?
Semaglutide is approved for type 2 diabetes (Ozempic injectable, Rybelsus oral tablet) and for chronic weight management in obesity (Wegovy injectable). Cardiovascular outcome trial data also support a cardiovascular risk reduction indication for Ozempic in adults with type 2 diabetes and established cardiovascular disease.
What are the brand names for semaglutide?
Semaglutide is sold as Ozempic (once-weekly injectable for type 2 diabetes), Wegovy (once-weekly injectable for obesity), and Rybelsus (once-daily oral tablet for type 2 diabetes). All three are manufactured by Novo Nordisk.
What is the typical dosage of semaglutide?
Injectable semaglutide doses used in cardiovascular and glycemic outcome trials ranged from 0.5 mg to 1 mg per week subcutaneously. Doses up to 2.4 mg/week are used for obesity (Wegovy). Oral Rybelsus is dosed at 3 mg, 7 mg, or 14 mg once daily. Dosing should be determined by a physician.
Is there an oral form of semaglutide?
Yes. Rybelsus is an FDA-approved oral tablet formulation of semaglutide for type 2 diabetes, taken once daily. The injectable formulations (Ozempic, Wegovy) are administered once weekly by subcutaneous injection and are used for both diabetes and obesity indications.
How long until semaglutide starts working?
Glucose-lowering effects begin early in treatment. Meaningful weight loss typically accumulates over months. Cardiovascular outcome trials and glycemic studies measured effects over 68–104 weeks of continuous therapy.
What are common side effects of semaglutide?
Nausea, vomiting, diarrhea, and constipation are among the most frequently reported gastrointestinal side effects, consistent with the GLP-1 agonist class. These are typically most pronounced during dose escalation and often diminish with continued use.
Who should not take semaglutide?
Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). People with a history of acute pancreatitis should use semaglutide only after careful physician evaluation, as case reports document semaglutide-associated acute pancreatitis.
What does the cardiovascular research on semaglutide show?
Peer-reviewed data identify associations between semaglutide use and reductions in major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Research has also explored associations with reduced atrial fibrillation incidence independent of weight loss. These findings come from clinical trials and observational data — individual cardiovascular risk should be assessed by a physician.
Can semaglutide be combined with other compounds?
A protocol under RCT investigation combines semaglutide with resistance exercise and a high-protein diet for lean mass preservation during weight loss therapy. An investigational combination with intranasal insulin for cognition in older adults with metabolic syndrome has also been explored in a feasibility trial. Combining semaglutide with other glucose-lowering agents requires physician supervision.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a selective GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. Real-world comparative data suggest tirzepatide produces greater weight loss on average, though individual responses vary. Both are FDA-approved and share similar class contraindications (MTC/MEN2 history).

References

  1. [1]

    Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.

    MacIsaac Richard J

    Future cardiology · 2025 · PMID 40458885

    View on PubMed →
  2. [2]

    Glucagon-like peptide-1 and atrial fibrillation incidence: Associations independent of weight loss.

    Palmisano Tiago, Verma Reeya, Guarraia David et al.

    Heart rhythm · 2026 · PMID 42029362

    View on PubMed →
  3. [3]

    Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.

    Kanbay Mehmet, Abdel-Rahman Sama Mahmoud, Guldan Mustafa et al.

    Clinical kidney journal · 2026 · PMID 42017027

    View on PubMed →
  4. [4]

    Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.

    Hepşen Sema, Haymana Cem, Ertepe Küçükgöde Gizem et al.

    Obesity facts · 2026 · PMID 42030208

    View on PubMed →
  5. [5]

    LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.

    Alawadhi Ameenah A, Alroudhan Dherar, Alsaeed Dalal J et al.

    BMJ open · 2026 · PMID 42020128

    View on PubMed →
  6. [6]

    Is There a Causal Link Between GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence.

    Danesh-Meyer Helen V, Rizzo Joseph F

    Clinical & experimental ophthalmology · 2026 · PMID 42020100

    View on PubMed →
  7. [7]

    Semaglutide-Associated Acute Pancreatitis in a Patient With Type 2 Diabetes Mellitus: A Case Report.

    Puri Piyush, Akhavan Michael, Shadan Jonathan et al.

    Cureus · 2026 · PMID 42017101

    View on PubMed →
  8. [8]

    Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.

    Overgaard Rune Viig, Birkhan Oscar, Rathor Naveen et al.

    Diabetes, obesity & metabolism · 2026 · PMID 42023428

    View on PubMed →
  9. [9]

    Liver benefits of early initiation of low-dose GLP-1 receptor agonists in newly diagnosed type 2 diabetes - A case report.

    Lee Joyce Y, Nguyen Huy, Nguyen Tan

    Journal of family medicine and primary care · 2026 · PMID 42023337

    View on PubMed →
  10. [10]

    Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.

    Corley Michael J, Pang Alina P S, Kitch Douglas W et al.

    npj aging · 2026 · PMID 42014432

    View on PubMed →
  11. [11]

    Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.

    Ganeshalingam Ashok A, Uhrenholt Nicolai, Arnfred Sidse et al.

    Diabetes care · 2026 · PMID 41778920

    View on PubMed →
  12. [12]

    Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge.

    Prasad Sai, Ahuja Aarushi, Katwa Laxmansa C et al.

    JCEM case reports · 2026 · PMID 42027588

    View on PubMed →
  13. [13]

    The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.

    Corcoran Eve, Kettlety Michael, Mogul Urwa et al.

    Molecular and cellular neurosciences · 2026 · PMID 42014236

    View on PubMed →
  14. [14]

    Body image in the age of GLP-1s: Emerging questions for research and practice.

    Craddock Nadia, Schneider Jekaterina

    Body image · 2026 · PMID 42030632

    View on PubMed →
  15. [15]

    Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study).

    Kapoor Nitin, Shaikh Shehla, Bhattacharya Saptarshi et al.

    Cardiovascular diabetology. Endocrinology reports · 2026 · PMID 42026662

    View on PubMed →
  16. [16]

    Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions.

    Hajibandeh Saba, Tao Yen-An, Hsieh Ming-Hui et al.

    Journal of the American Pharmacists Association : JAPhA · 2026 · PMID 42025961

    View on PubMed →
  17. [17]

    Effect of Weight-Neutral Treatment With Semaglutide or Tirzepatide on β-Cell Identity in db/db Mice.

    Deng Zhaobin, Zheng Dongxu, Son Jinsook et al.

    Acta physiologica (Oxford, England) · 2026 · PMID 41354136

    View on PubMed →
  18. [18]

    Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide.

    McLean Brent A, Wong Chi Kin, Kaur Kiran Deep et al.

    JCI insight · 2021 · PMID 34673572

    View on PubMed →
  19. [19]

    The effect of Semaglutide on mitochondrial function and insulin sensitivity in a myotube model of insulin resistance.

    Spry Emmalie R, Travis Kipton B, Ragland Kayla J et al.

    Molecular and cellular endocrinology · 2025 · PMID 40752656

    View on PubMed →
  20. [20]

    NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice.

    Bultinck Jennyfer, Yuan Shendong, Cantuti-Castelvetri Ludovico et al.

    Molecular metabolism · 2026 · PMID 41242536

    View on PubMed →
  21. [21]

    Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control.

    Ábel Tatjana, Csobod Csajbókné Éva

    International journal of molecular sciences · 2026 · PMID 41683613

    View on PubMed →
  22. [22]

    A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk — Study rationale and design.

    Davidy Tal, Yore Iscka, Cukierman-Yaffe Tali et al.

    Mechanisms of ageing and development · 2024 · PMID 38159613

    View on PubMed →
  23. [23]

    Differential Effects of Semaglutide and Colchicine on Atrial Remodeling in Rats with Reduced Ejection Fraction after Myocardial Infarction.

    Levi Or, Dalal Noam, Komissar Aviv et al.

    Europace · 2026 · PMID 42015513

    View on PubMed →
  24. [?]

    Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy.

    Shah Jui, Makwana Bhargav, Panchal Krisha et al.

    American journal of ophthalmology · 2026 · PMID 42025665

    View on PubMed →
  25. [?]

    Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure.

    Costa Thomaz Alexandre, Vest Amanda R, Harrington Josephine

    Current opinion in cardiology · 2026 · PMID 41802118

    View on PubMed →
  26. [?]

    Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study.

    Nicolau Joana, Nadal Antoni, Sanchís Pilar et al.

    Clinical and experimental dermatology · 2026 · PMID 41137591

    View on PubMed →
  27. [?]

    GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction.

    Ha Joy, Lester Ethan, De May Henning et al.

    Journal of reconstructive microsurgery · 2026 · PMID 42013898

    View on PubMed →

Compare Semaglutide with…

Semaglutide vs Tirzepatide

Semaglutide · Tirzepatide

View comparison →